VIVEBIOTECH S.L. is a spin-off promoted by the Inbiomed Foundation, which specialises in gene transfer technologies, and in particular those related to the production of viral vectors under GMP conditions, and their gene therapy applications. It is located at the Gipuzkoa Science and Technology Park in San Sebastian. VIVEBIOTECH aims to develop gene therapy products for clinical trials, in strict compliance with requirements established under current legislation, and in accordance with best practice guidelines. The VIVEbioTECH facilities are fitted with a clean room for the production of medicines for Stage I/II clinical trials. Besides the GMP-grade viral vectors, VIVEbioTECH produces lentivirus, adenovirus, and adeno-associated virus (UNE-EN ISO 9001:2008) providing services to academic researchers and industry for in vitro and in vivo research studies. VIVEBIOTECH has also developed the ZELIGEN platform, a platform for deriving viral vectors from modified lentivirus, in order to improve bio-security and extend its therapeutic indications. LentiSoma is the product in the most advanced development stage within the ZELIGEN platform. A self-replicating episomal lentiviral vector which is a prototype for a new generation of viral vectors, it is covered by intellectual property rights (EPO P9994PC00 Stable Episomes Based On Non-integrative Lentiviral Vectors, priority date November 2013).